By Nick Carney, F.Hoffmann-La Roche A recent panel discussion at the DIA Europe 2021 virtual congress chaired by Meni Styliadou (Takeda, H2O Project Leader) titled “Laying the foundation for a value-based, patient-centered, and outcome-driven healthcare system in Europe” provided the opportunity to present the vision of IMI H2O and discuss in project the context of these healthcare […]
The Health Outcomes Observatory (H2O) project kicked off on 1 October 2020 with the aim to equip patients with the tools to measure their outcomes in a standardised way, whilst giving them full control of their data. This is the first-ever attempt at scale to collect and incorporate patient outcomes into healthcare decision making at an individual and population level. And it […]
The foundation work for establishing the national and European observatories is well under way. The principles behind the governance of these new bodies have been written and agreed by the H2O Steering Committee at the end of January. These nine principles, together with the legal groundwork and the description of data flows and consents, form […]
The Innovative Medicines Initiative (IMI) has approved a 20.6 million euros project to create an unprecedented, standardised data governance and infrastructure system across Europe to incorporate patients’ opinions and preferences in decisions affecting their individual health and those of the entire community. Lead by the pharmaceutical company Takeda and coordinated by Vienna Medical University, H2O […]
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/